5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disease progression or maybe the participants are unable to tolerate the study drugs.For all move cytometry experiments, 10,000 cells for every replicate have been a